Not rendering correctly? View this email as a web page here.
The FDA Has Approved America’s First Gene-Editing Therapy—Casgevy, and More...
facebook-icon-white
x
instagram-icon-white
ARK Invest logo

ARK • Disrupt

It's Your weekly innovation newsletter

It's Monday, December 11, 2023. Please enjoy ARK's weekly newsletter curated by our thematic research team and designed to keep you engaged with disruptive innovation.

The FDA Has Approved America’s First Gene-Editing Therapy—Casgevy

ARK Invest_Headshot_Ali Urman_Edit 5

By Ali Urman | @aurmanARK
Analyst

Following Bitcoin's Lead?

'In The Know' with Cathie Wood

Published: December 8, 2023

WATCH

Google Made Some Unforced Errors During Its Highly Anticipated Gemini Launch

ARK Invest_Headshot_Frank Downing_Edit 5

By Frank Downing | @DowningARK
Director of Research, Next Generation Internet

AMD Is Competing With Nvidia for Inference Workloads

ARK Invest_Headshot_Jozef Soja_Edit 5

By Jozef Soja | @JozefARK
Research Associate

“Animate Anyone” Could Disrupt Video Production

ARK Invest_Headshot_Andrew Kim_Edit 5

By Andrew Kim | @andrewkimARK
Research Associate

Fact of the Week

Last week, AMD officially launched its MI300X accelerator which, according to the company, outperforms Nvidia's H100 by a factor of 1.4x in inferencing Llama 2 70B.

Source: https://www.amd.com/en/corporate/events/advancing-ai.html

Copyright © 2023 ARK Investment Management LLC, All rights reserved.

200 Central Avenue,

St. Petersburg, FL 33701 United States

You received this email because you are subscribed to Research Newsletters from ARK Investment Management LLC.

Unsubscribe from ARK emails or choose the types of emails you want to receive. Unsubscribe from all.